Skip to main content

Castle Creek Biosciences, Inc. (CCBS)

Castle Creek Biosciences will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet

Company Description

Castle Creek Biosciences is a clinical-stage cell and gene therapy company focused on developing and commercializing disease-modifying therapies for patients suffering from rare diseases for which there is a lack of available treatment options.

Our proprietary platform serves as the foundation for developing personalized, targeted and redosable cell-based gene therapy product candidates. At present, our novel in-house manufacturing process entails collecting minimally invasive skin biopsies from patients, and transducing fibroblast cells with a third-generation self-inactivating lentiviral vector to express a targeted protein of interest.

The genetically modified cells are then intradermally administered to the disease site with the goal of expressing the target protein in the desired region.

As part of this process, we also create a personalized cell bank of genetically modified autologous fibroblasts that can be stored cryogenically, serving as a repository for the patient’s long term drug product needs.

Our most advanced product candidate, D-Fi, is currently in a Phase 3 clinical trial for the treatment of recessive dystrophic epidermolysis bullosa, or RDEB, with topline data expected in the second half of 2022.

We are initially prioritizing our clinical-stage product candidates for skin and connective tissue diseases, with the goal of expanding into other rare diseases and broader indications where patients have limited or no therapeutic options.

Castle Creek Biosciences, Inc.
CountryUnited States
IPO DatePending
IndustryPharmaceutical Preparations
CEOMatthew Gantz

Contact Details

405 Eagleview Boulevard
Exton, PA 19341
United States
Phone(484) 713-6000

Stock Details

Ticker SymbolCCBS
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
CIK Code1756702
Employer ID83-1984773

Key Executives

Matthew GantzPresident, Chief Executive Officer, Director
Mary Spellman, M.D.Chief Medical Officer, Senior Vice President of Research & Development
Gregory WujekChief Commercial Officer
Gregory MacMichael, Ph.D.Chief Technology Officer
W. Bradford MiddlekauffChief Legal Officer
Jeffrey S. AroninDirector, Chairman
Antonio J. GraciasDirector
R. Mark GrafDirector